The triple-receptor study
Coskun et al. characterized retatrutide as a triple agonist at glucagon, GIP, and GLP-1 receptors in receptor assays and mouse experiments. Coskun et al., Cell Metabolism, 2022 ↗
The dual-receptor study
Coskun et al. characterized tirzepatide as a dual GIP and GLP-1 receptor agonist in receptor assays, mouse experiments, and Phase 1 clinical work. Coskun et al., Molecular Metabolism, 2018 ↗